Molecular Partners Appoints Martin Steegmaier as Chief Scientific Officer.

Molecular Partners, a clinical-stage biotech company, has appointed Martin Steegmaier as Chief Scientific Officer and member of the Executive Committee. Steegmaier has extensive experience in oncology drug development from senior research roles at Roche, MorphoSys, Boehringer Ingelheim, and CSO at SOTIO Biotech. His appointment is effective October 1, 2025.

Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, has appointed Martin Steegmaier, Ph.D., as its Chief Scientific Officer (CSO) and a member of the company’s Executive Committee. Steegmaier will take on his new role effective October 1, 2025. [1]

Steegmaier brings a wealth of experience in oncology drug development from senior research roles at major biotech and pharmaceutical companies. He has previously held positions such as Head of Research at MorphoSys, focusing on the development of antibody-based therapeutics in immuno-oncology and hematology-oncology. He also served as Head of Discovery for the Large Molecule Research organization at the Roche Innovation Center in Munich and at Boehringer Ingelheim in oncology drug discovery. Most recently, he was the CSO at SOTIO Biotech, a clinical-stage company developing immunotherapies for cancer. [1]

Patrick Amstutz, Ph.D., CEO of Molecular Partners, expressed his excitement about Steegmaier’s appointment. “I am delighted to welcome Martin Steegmaier to Molecular Partners, where his extensive expertise in oncology, business, and leadership will provide further impetus to our efforts to deliver unique cancer therapies,” Amstutz said. “Martin’s experience will be invaluable in leading the research organization and as we continue to innovate and advance our pipeline of targeted DARPin therapeutics for cancer patients, including Radio-DARPins and Switch-DARPins for logic-gated immune cell activation.” [1]

Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. [1]

Steegmaier holds a Ph.D. in biochemistry from the University of Basel and an MBA from the Edinburgh Business School. He graduated from Northern Arizona University. [1]

References:
[1] https://www.globenewswire.com/news-release/2025/08/21/3136829/0/en/Molecular-Partners-appoints-Martin-Steegmaier-as-Chief-Scientific-Officer-to-drive-discovery-of-next-gen-DARPin-therapeutics.html